Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Firsov

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1991
Age dependence of erythromycin rectal bioavailability in childrenL S Stratchunsky, A D Nazarov, A A Firsov, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|August 1, 1985
[Clinical pharmacokinetics of the antitumor antibiotic reumycin: an analysis of individual variability]A A Firsov, S V Geodakian, M R Lichinitser, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2001
The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient dosesS H Zinner, A A Firsov, D Gilbert, et al.
Antibiotiki|August 1, 1981
[Sisomicin pharmacokinetics in rat tissues in single and long-term administration]L V Umnova, V G Koroleva, T Ia Goncharskaia, et al.
Antibiotiki|April 1, 1981
[Comparative characteristics of the methods for assessing aminoglycoside extraction with the artificial kidney tobramycin clearance and dialyzability]A A Firsov, N S Bogomolova, O S Treskina, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|September 1, 1989
[Individual schedule of administration of aminoglycosides with reference to anatomo-physiological and pathological factors]A A Firsov, L B Kashina, G I Lukomskiĭ, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic modelA A Firsov, S N Vostrov, O V Kononenko, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|April 1, 1996
[Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic]A A Firsov, V S Dombrovskiĭ, I B Kadenatsi, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|August 1, 1988
[Pharmacokinetic study of implantable gentamycin preparations. I. Antibiotic pharmacokinetics in the implantation area and an evaluation of the prolonged effect of the preparations]A D Nazarov, A A Firsov, P S Navashin, et al.
Antibiotiki|July 1, 1983
[Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney]S M Navashin, O S Treskina, A A Firsov, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
European Journal of Drug Metabolism and Pharmacokinetics|January 1, 1991
Age dependence of erythromycin rectal bioavailability in childrenL S Stratchunsky, A D Nazarov, A A Firsov, et al.
Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology|August 1, 1985
[Clinical pharmacokinetics of the antitumor antibiotic reumycin: an analysis of individual variability]A A Firsov, S V Geodakian, M R Lichinitser, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2001
The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient dosesS H Zinner, A A Firsov, D Gilbert, et al.
Antibiotiki|August 1, 1981
[Sisomicin pharmacokinetics in rat tissues in single and long-term administration]L V Umnova, V G Koroleva, T Ia Goncharskaia, et al.
Antibiotiki|April 1, 1981
[Comparative characteristics of the methods for assessing aminoglycoside extraction with the artificial kidney tobramycin clearance and dialyzability]A A Firsov, N S Bogomolova, O S Treskina, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|September 1, 1989
[Individual schedule of administration of aminoglycosides with reference to anatomo-physiological and pathological factors]A A Firsov, L B Kashina, G I Lukomskiĭ, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic modelA A Firsov, S N Vostrov, O V Kononenko, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|April 1, 1996
[Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic]A A Firsov, V S Dombrovskiĭ, I B Kadenatsi, et al.
Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]|August 1, 1988
[Pharmacokinetic study of implantable gentamycin preparations. I. Antibiotic pharmacokinetics in the implantation area and an evaluation of the prolonged effect of the preparations]A D Nazarov, A A Firsov, P S Navashin, et al.
Antibiotiki|July 1, 1983
[Pharmacokinetic basis for using tobramycin and sisomicin in treating pyelonephritis of the transplanted kidney]S M Navashin, O S Treskina, A A Firsov, et al.
Pageof 11